Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update

202483 citationsReviewdiamond Open Access

Authors

Kevin McFarthing · Parkinson's UK

Sue Buff · Parkinson's Institute and Clinical Center

Gary Rafaloff · Parkinson's Foundation

Kenneth Pitzer

Brian Fiske · Michael J. Fox Foundation

Anaya Navangul · Parkinson's UK

Katelyn Beissert · Parkinson's UK

Abstract

The drug development pipeline for PD remains in a robust state with a wide variety of approaches being developed and evaluated in Phase 1 and 2. Yet again, however, only a limited number of DMTs are transitioning to Phase 3.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Autism Spectrum Disorder Research Nuclear Receptors and Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Parkinson s Disease

Volume 14, Issue 5, pp. 899-912

DOI: 10.3233/jpd-240272

Field-Weighted Citation Impact: 30.36